Detalhe da pesquisa
1.
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
Rev Esp Enferm Dig
; 114(2): 89-95, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33947195
2.
Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.
Rev Esp Enferm Dig
; 114(2): 118-119, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34517718
3.
Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.
Rev Esp Enferm Dig
; 114(5): 272-279, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33393332
4.
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.
Gastroenterol Hepatol
; 45(3): 165-176, 2022 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-34051313
5.
Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results.
Rev Esp Enferm Dig
; 113(2): 92-97, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33371692
6.
Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.
Rev Esp Enferm Dig
; 112(10): 756-761, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32954770
7.
Vedolizumab response in inflammatory bowel disease. Two years of follow-up.
Rev Esp Enferm Dig
; 112(7): 555-558, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32579005
8.
Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?
Rev Esp Enferm Dig
; 112(11): 821-825, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054301
9.
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
Rev Esp Enferm Dig
; 110(9): 564-570, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29893581
10.
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.
Rev Esp Enferm Dig
; 109(8): 552-558, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28617030
11.
Evolution of the incidence of inflammatory bowel disease in Southern Spain.
Rev Esp Enferm Dig
; 109(11): 757-760, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28776379
12.
Initial experience with golimumab in clinical practice for ulcerative colitis.
Rev Esp Enferm Dig
; 108(3): 129-32, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26786341
13.
Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.
Therap Adv Gastroenterol
; 16: 17562848231191670, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37655058
14.
Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
Rev Esp Enferm Dig
; 104(2): 59-64, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22372798
15.
Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity.
Endosc Int Open
; 9(2): E130-E136, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33532549
16.
Erythema Nodosum: As an Extraintestinal Manifestation or Complication in Ulcerative Colitis?
Inflamm Bowel Dis
; 26(7): e74-e75, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32448913
17.
Retroperitoneal hematoma in Crohn's disease patient with warfarin therapy.
Rev Esp Enferm Dig
; 106(5): 364-6, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25287245
18.
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.
Therap Adv Gastroenterol
; 12: 1756284819858052, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31258621
19.
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
World J Gastroenterol
; 24(46): 5288-5296, 2018 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30581277
20.
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study / Rapidez de la respuesta clínica a adalimumab y mejora de la calidad de vida en la enfermedad de Crohn luminal: estudio RAPIDA
Gastroenterol. hepatol. (Ed. impr.)
; 45(3): 165-176, Mar. 2022. tab, graf
Artigo
em Inglês
| IBECS (Espanha) | ID: ibc-204204